Katherine Cristiano
Rheumatology · Bellevue, WANPI 1497472500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 25.5% of the total. Reporting peaked in 2023 at $2,537 and has fallen 89.4% since, to $268 in 2025.
Across 171 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$645
- E.r. Squibb & Sons, L.L.C.$318
- Pfizer$273
- GSK$268
- AstraZeneca$260
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,12898%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $1,071 |
| Amgen(2 entities) | 26 | $645 |
| E.r. Squibb & Sons, L.L.C. | 8 | $318 |
| Pfizer | 11 | $273 |
| GSK | 10 | $268 |
| AstraZeneca(2 entities) | 10 | $260 |
| Johnson & Johnson | 9 | $232 |
| Organon | 9 | $159 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $119 |
| Radius Health, Inc. | 6 | $107 |
| Sobi, Inc | 4 | $103 |
| UCB, Inc. | 3 | $103 |
| Sandoz | 3 | $69 |
| Lilly USA, LLC | 3 | $62 |
| Aurinia Pharma U.S., Inc. | 2 | $53 |
| Novartis | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Endotronix, Inc. | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $34 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Sanofi | 1 | $26 |
| Medtronic | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,202 in reported general payments places this provider in the 75th percentile of 157 rheumatology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 50 | $1,631 |
| Pilocarpine Hcl | 14 | $1,111 |
| Colchicine | 21 | $692 |
| Tramadol Hcl | 79 | $633 |
| Prednisone | 132 | $501 |
| Celecoxib | 20 | $387 |
| Alendronate Sodium | 52 | $371 |
| Gabapentin | 54 | $368 |
| MethotrexateMethotrexate Sodium | 60 | $325 |
| Nifedipine ErNifedipine | 13 | $258 |
| Pregabalin | 16 | $238 |
| Omeprazole | 40 | $224 |
| Allopurinol | 22 | $157 |
| Folic Acid | 15 | $127 |
| Meloxicam | 22 | $47 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Bellevue
- Arinola DadaBellevue$69K
- Viviane BuninBellevue$38K
- Kent TaBellevue$22K
- Justin PutzBellevue$4K
- Christopher DinhBellevue$2K
- Stanford PengSeattle$3.5M
- Jeff PetersonBothell$2.3M
- Philip MeaseSeattle$2.1M
- Robert EttlingerTacoma$232K
- Richard JimenezBothell$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.